Jorge Diego, MD
Nephrology · Shelbyville, INNPI 1669400198
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,450 of the $81,117 with a category attached, or 80.7%. 39 manufacturers reported payments, led by AstraZeneca at 57.3% of the total. Reporting peaked in 2019 at $33,124 and has fallen 97.9% since, to $680 in 2025. Among nephrology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $273.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$47K
- Mallinckrodt Enterprises LLC$25K
- Mallinckrodt Hospital Products Inc.$3K
- AbbVie$3K
- Novo Nordisk$568
- Vifor Pharma, Inc.$374
- plus $3K from 33 others
What the payments were for
- Speaking & faculty fees$65,45081%
- Travel & lodging$7,73810%
- Food & beverage$7,7039%
- Education$2270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,117 in reported general payments places this provider in the 95th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 41 | $168,558 |
| FarxigaDapagliflozin Propanediol | 112 | $127,402 |
| RayaldeeCalcifediol | 50 | $99,841 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $47,941 |
| JardianceEmpagliflozin | 29 | $33,625 |
| PrezcobixDarunavir/Cobicistat | 13 | $32,578 |
| KerendiaFinerenone | 14 | $22,769 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $20,606 |
| MounjaroTirzepatide | 16 | $18,931 |
| OzempicSemaglutide | 18 | $18,836 |
| VeltassaPatiromer Calcium Sorbitex | 14 | $16,585 |
| Febuxostat | 14 | $4,992 |
| Torsemide | 238 | $3,872 |
| Eplerenone | 26 | $2,413 |
| Nebivolol Hcl | 45 | $2,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $149 | $168,55841 claims |
| AstraZenecaFarxiga, Lokelma | $46,519 | $148,008147 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $113 | $99,84150 claims |
| Boehringer IngelheimJardiance | $153 | $33,62529 claims |
| Johnson & JohnsonPrezcobix | $17 | $32,57813 claims |
| BayerKerendia | $108 | $22,76914 claims |
| Novo NordiskOzempic | $568 | $18,83618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 238 nephrology providers in Indiana.
Other nephrology in Shelbyville
- Anupama MohanramShelbyville$11K
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Narothama Reddy AeddulaEvansville$125K
- Gaurav VermaTerre Haute$125K
- Manish GeraTerre Haute$113K
- Bruce MolitorisIndianapolis$108K
- Michael KrausIndianapolis$92K
- Muhammad MujtabaIndianapolis$71K
- Andrew OshaughnessyFort Wayne$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.